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Introduction
For several years, mesenchymal stem cells (MSCs; also 
called mesenchymal stromal cells) have been largely 
studied and used as a new therapeutic tool for a number 
of clinical applications, in particular for the treatment of 
rheumatologic disorders. MSCs indeed have therapeutic 
potential for bone and joint diseases due to their 
multipotent diﬀ  erentiation abilities and the secretion of a 
variety of cytokines and growth factors that confer on 
them anti-ﬁ   brotic, anti-apoptotic, pro-angiogenic and 
immunosuppressive properties. Th   ey are currently being 
tested in several clinical trials for such diverse appli  ca-
tions as osteoarthritis, osteogenesis imperfecta, articular 
cartilage defects, osteonecrosis and bone fracture. More-
over, good manufacturing practices for the production of 
clinical-grade MSCs  at high expansion rates without 
transformation are now well established [1]. Here, we 
review the present knowledge on the mecha  nisms 
underlying the therapeutic properties of MSCs and their 
applications in animal models and clinics in the ﬁ  elds of 
bone and cartilage repair, chronic inﬂ  ammatory  or 
degenerative disorders, as well as genetic diseases.
Defi  nition of mesenchymal stem cells: location and 
characterization
MSCs were ﬁ  rst identiﬁ  ed in the bone marrow (BM) [2] 
but are now described to reside in connective tissues and 
notably in adipose tissue (AT) [3], placenta [4], umbilical 
cord [5], dental pulp [6], tendon [7], trabecular bone [8] 
and synovium [9]. It has also been suggested that MSCs 
could reside in virtually all post-natal organs and tissues 
[10]. BM and AT are, however, the two main sources of 
MSCs for cell therapy due to high expansion potential 
and reproducible isolation procedures. Historically, the 
ﬁ  rst characterized MSCs derived from BM remain the 
most intensively studied and are still the reference. AT-
derived MSCs (ASCs) are easier to isolate in high 
numbers. Nevertheless, while they display characteristics 
similar to BM-MSCs, their transcriptomic and proteomic 
proﬁ  les show speciﬁ  cities particular to the tissue origin 
[11]. MSCs have also been described to reside in a 
perivascular location and to express markers speciﬁ  c for 
pericytes [12,13]. However, in AT, ASCs are mainly 
located in the stroma around the adipocytes and only few 
of them have a perivascular location. Importantly, in the 
tissue, none or very few ASCs express pericyte markers, 
even those that are located around the vessels [14].
MSCs are deﬁ  ned according to three criteria proposed 
by the International Society for Cellular Th  erapy [15]. 
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population that is isolated by its property of adherence to 
plastic. In culture, MSCs are able to develop as ﬁ  broblast 
colony forming-units. Second, MSCs are distinguished 
by their phenotype: MSCs express the cell surface 
markers CD73, CD90 and CD105 and are negative for 
CD11b, CD14, CD34, CD45 and human leukocyte 
antigen (HLA)-DR. More recently, the CD271 marker 
was used to isolate highly enriched BM-MSC populations 
[16]. Whereas BM-MSCs are negative for the CD34 
marker, native ASCs can be isolated according to CD34 
expression, although this rapidly disappears with cell 
proliferation in vitro [14,17]. Th   e third criterion to deﬁ  ne 
MSCs, based on a functional standard, is their capacity to 
diﬀ   erentiate into at least three mesenchymal lineages, 
namely bone, fat and cartilage.
Functional properties of mesenchymal stem cells
Diﬀ  erentiation capacity and paracrine signaling are both 
properties relevant for therapeutic applications of MSCs. 
MSC diﬀ  erentiation contributes by regenerating damaged 
tissue, whereas MSC paracrine signaling regulates the 
cellular response to injury.
Diff  erentiation properties
MSCs are an attractive source of cells for bone and 
cartilage engineering because of their osteogenic and 
chondro genic  potential. Th  eir diﬀ  erentiation capacity is 
generally shown in vitro using speciﬁ  c culture conditions 
but also in vivo in diﬀ  erent animal models [18]. Besides 
this trilineage potential, MSCs can also diﬀ  erentiate into 
myocytes [19], tendinocytes [20], cardiomyocytes [21], 
neuronal cells with neuron-like functions [22,23] and 
other cell types. Th  e diﬀ  erentiation potential is depen-
dent on environmental factors, such as growth factors, 
but also physical parameters, such as oxygen tension, 
shear and compressive forces, and elasticity of the 
extracellular three-dimensional environment.
Paracrine properties
MSCs release various soluble factors that inﬂ  uence the 
microenvironment by either modulating the host immune 
response or stimulating resident cells.
Th  e immunomodulatory properties of MSCs, charac-
ter  ized by the capacity to inhibit the proliferation and 
function of all immune cells, have been largely described 
both in vitro and in vivo (reviewed in [24]). Immuno-
modulation requires the preliminary activation of MSCs 
by immune cells through the secretion of the pro-
inﬂ   ammatory cytokine IFN-γ, together with TNF-α, 
IL-1α or IL-1β [25,26]. Th   e induction of MSC immuno-
modulation is principally mediated by soluble mediators. 
Among these, indoleamine 2,3-dioxygenase has been 
shown to be a major player in human MSCs but absent or 
poorly expressed in murine cells, while nitric oxide is 
expressed at low levels in human MSCs but at high levels 
in murine MSCs following IFN-γ stimulation [26]. 
Transforming growth factor (TGF)-β1, hepatocyte 
growth factor (HGF), heme oxygenase  1, IL  6, leukemia 
inhibitory factor, HLA  G5, IL-10 and IL-1 receptor 
antago  nist (IL-1RA) as well as prostaglandin E2 have 
been proposed as other mediators involved in MSC-
mediated immunomodulation (reviewed in [24]). MSCs 
suppress B- and T-cell proliferation and alter their func-
tion, inhibit the proliferation of activated natural killer 
cells, interfere with the generation of mature dendritic 
cells from monocytes or CD34+ progenitor cells, and 
induce an immature dendritic cell phenotype [27,28]. 
Finally, MSCs inhibit Th   17 cell diﬀ  erentiation and induce 
fully diﬀ  erentiated Th   17 cells to exert a T cell regulatory 
phenotype [29].
Although soluble mediators are the main actors in 
MSC immunosuppression, cell-cell interactions have 
been shown to be involved in this process. Recently, toll-
like receptor (TLR) stimulation has been shown to 
modulate the action of MSCs on the immune system. 
Indeed, TLR4-primed MSCs, or MSC1, mostly elaborate 
pro-inﬂ  ammatory mediators, while TLR3-primed MSCs, 
or MSC2, express mostly immunosuppressive ones [30].
Th   e trophic properties of MSCs are related to the tissue 
regeneration process through bioactive factors. Th  ese 
factors may act directly, triggering intracellular mecha-
nisms of injured cells, or indirectly, inducing secretion of 
functionally active mediators by neighboring cells. MSCs 
are capable of attenuating tissue injury, inhibiting ﬁ  brotic 
remodeling and apoptosis, promoting angiogenesis, 
stimu  lating stem cell recruitment and proliferation, and 
reducing oxidative stress. As an example, in a hamster 
heart failure model, intramuscularly injected MSCs, or 
even more importantly MSC-conditioned medium, signi-
ﬁ    cantly improve cardiac function. Improvement occurred 
via soluble mediators acting on proliferation and angio-
genesis, resulting in higher numbers of myocytes and 
capillaries, and on apoptosis and ﬁ   brosis, which were 
signiﬁ  cantly reduced [31]. Th   e prominent factors identi-
ﬁ   ed in these processes were HGF and vascular endo-
thelial growth factor (VEGF). Th  e authors demonstrate 
the activation of the JAK-STAT3 axis in myocytes, which 
increases the expression of the target genes HGF and 
VEGF [32]. Activation of the STAT3 pathway is crucial 
since its inhibition by TLR4 activation inhibits MSC-
mediated cardioprotection [33]. Secretion of VEGF by 
MSCs also attenuates renal ﬁ  brosis  through  immune 
modulation and remodeling properties in diﬀ  erent 
models of kidney injury [34,35]. Th   e other mediators that 
are important actors during tissue remodeling and 
ﬁ  brosis formation are matrix metalloproteinases (MMPs) 
and tissue inhibitors of MMP (TIMPs). MSC-secreted 
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physiological conditions in their niche and in pathological 
situations [36,37].
Chemotactic properties
Injured tissues express speciﬁ  c receptors or ligands that 
are believed to trigger the mobilization of MSCs into the 
circulation, facilitating traﬃ   cking, adhesion and inﬁ  ltra-
tion of MSCs to the damaged or pathological tissues, in a 
mechanism similar to the recruitment of leukocytes to 
sites of inﬂ  ammation. In the damaged tissues, MSCs are 
believed to secrete a broad spectrum of paracrine factors 
that participate in the regenerative microenvironment 
and regulate immune inﬁ  ltration [38]. Administration of 
MSCs, either systemically or locally, has been reported to 
contribute to tissue repair, suggesting the need to 
enhance the pool of endogenous MSCs with exogenously 
administered MSCs for eﬃ   cient repair. A better under-
standing of MSC traﬃ     cking and homing mechanisms 
should help in designing novel therapeutic options to 
compensate for a deﬁ  ciency in the number or function of 
MSCs that may occur in injured tissues.
Therapeutic applications of MSCs in rheumatology
MSCs for bone and cartilage repair
Interest in using MSCs for tissue engineering has been 
validated in numerous pre-clinical models and is under 
evaluation in clinics. At least 16 clinical trials are 
recruiting for the therapeutic application of MSCs for 
cartilage defects, osteoporosis, bone fracture, or osteo-
necrosis. For successful tissue engineering approaches, 
implantation of MSCs will require the use of growth and 
diﬀ  erentiation factors that will allow the induction of the 
speciﬁ  c diﬀ  erentiation pathways and the maintenance of 
the bone or chondrocyte phenotype together with an 
appropriate scaﬀ   old to provide a three-dimensional 
environ ment.  Deﬁ  ning the optimal combination of stem 
cells, growth factors and scaﬀ   olds is thus essential to 
provide functional bone and cartilage.
Bone engineering strategies are warranted in cases of 
large bone defects or non-union fractures, which remain 
a serious problem as the associated loss of function 
considerably impairs the quality of life of aﬀ  ected 
patients. A vast variety of bone graft substitutes is already 
commercially available or under intense pre-clinical 
investigation to evaluate their appropriateness to serve as 
biomaterials for tissue engineering strategies (reviewed 
in [39]). Brieﬂ   y, bone substitutes are assigned to the 
group of either inorganic (mostly calcium phosphate- or 
calcium sulphate-based materials, or bioactive glasses) or 
organic matrices (natural processed bone graft or 
synthetic polymers). Moreover, it has to be stressed that 
the success of bone graft substitutes needs a fun  ctional 
vascular network to obtain high quality osseous tissue. 
Enhanced vascularisation is generally achieved by the 
provision of angiogenic growth factors that have been 
shown to increase bone healing [40]. To date, cortico-
cancellous bone grafts remain the most frequently used 
way of reconstructing large bone segments. Despite 
promis  ing reports on the potential of bone engineering, 
particularly for oral and maxillofacial surgeries, these 
innovative therapeutic strategies have so far been too 
sporadic, and with low numbers of patients, to give 
interpretable results. Further eﬀ  orts are needed to state 
more precisely the indications in which tissue engineered 
constructs could replace conventional therapies and 
improve clinical outcome of patients.
After traumatic or pathological injury, the capacity of 
adult articular cartilage to regenerate is limited. Th  e 
current proposed surgeries (microfracture, osteochondral 
auto- or allografts, or cell-based therapies using chondro-
cytes) may lead to ﬁ  brocartilage and not restore hyaline 
articular cartilage in the long term. Several kinds of 
combined scaﬀ   olds have been evaluated for cartilage 
engineering using MSCs (reviewed in [41]). More 
recently, micron-sized ﬁ  bers, produced by the electro-
spinning technique, were shown to provide a structure 
and proper  ties comparable to the cartilage extracellular 
matrix and to enhance chondrogenesis [42]. Eﬀ  orts are 
being made to improve scaﬀ  olds by combining several 
biomaterials (poly(lactic-co-glycolic acid) sponge and 
ﬁ  brin gel) with an inducing factor (TGF-β1) with satis-
factory results [43]. Recently, our group has shown that 
MSC-coated pharmacologically active micro  carriers 
releasing TGF-β3 implanted in severe combined immu  no-
deﬁ   ciency (SCID) mice resulted in the formation of 
cartilage, suggesting that they could repre  sent a promis-
ing injectable biomedical device for cartilage engineering 
[44]. An alternative way to avoid direct transplantation of 
MSCs for tissue engineering is to recruit endogenous 
progenitor cells. Indeed, the replace  ment of the proximal 
condyle in a rabbit by a TGF-β3-infused bioscaﬀ  old 
resulted, 4 months later, in a scaﬀ  old fully covered with 
avascular hyaline cartilage in the articular surface. Th  e 
scaﬀ   old was also integrated within the regenerated 
subchondral bone, suggesting that the regeneration was 
probably due to homing of endogenous cells [45]. 
Although much progress has been made in the manipu-
lation of cells and constructs for cartilage engineering, 
the generation of functional repaired tissue remains to be 
optimized.
MSCs for treatment of genetic diseases
Recent advances in stem cell research have prompted the 
development of cell-based therapies to replace cells that 
are deﬁ   cient in genetic diseases [46]. Osteogenesis 
imperfecta is a rare genetic disorder due to abnormal 
collagen type I production by osteoblasts, resulting in 
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and considerably shortened stature. To replace defective 
osteoblasts, the infusion  of allogeneic whole BM or 
isolated BM-MSCs producing normal collagen type I was 
evaluated in two studies [47,48]. Although linear growth 
rate, total body bone mineral content, and fracture rate 
improved in some patients, the relatively short-term 
follow-up prevented the authors from drawing ﬁ  rm 
conclusions about the eﬃ     cacy of MSC therapy. In a 
subsequent study with infusions of labelled BM-MSCs, 
Horwitz and colleagues reported that engraftment was 
evident in one or more sites, including bone, skin, and 
marrow stroma, in ﬁ  ve out of six patients. Th  ese ﬁ  ve 
patients had an acceleration of growth velocity during the 
ﬁ  rst 6 months after infusion [48]. Moreover, the trans-
plantation of allogeneic foetal liver-derived MSCs in a 
foetus with severe osteogenesis imperfecta led to 0.3% of 
cell engraftment and diﬀ  erentiation of the donor cells 
into osteocytes until more than 9 months after transplant 
[49].
Hypophosphatasia, another metabolic bone disease, is 
a rare, heritable disease due to deﬁ  cient activity of tissue 
nonspeciﬁ  c alkaline phosphatase, often causing death in 
the ﬁ  rst year of life due to respiratory complications. In a 
young girl, transplantation of 5/6 HLA-matched T-cell-
depleted BM resulted in clinical and radiographic 
improve  ment without correction of the biochemical 
features of hypophosphatasia during the ﬁ  rst 6 months 
[50]. However, skeletal demineralization occurred 
13  months after transplantation and the decision was 
therefore taken to infuse BM cells that had been ex-
panded  ex vivo. Six months later, considerable, lasting 
clinical and radiographic improvement ensued, still 
without correction of her biochemical abnormalities. 
Despite the small number of studies, patients with meta-
bolic bone diseases have beneﬁ  ted from allogeneic MSC 
therapy.
MSCs for the treatment of infl  ammatory disorders
Due to their immunosuppressive properties, MSCs may 
be of interest in the treatment of inﬂ  ammatory disorders 
such as rheumatoid arthritis, which is the most promi-
nent inﬂ  ammatory rheumatic disease. To date, conﬂ  icting 
results have been reported using the collagen-induced 
arthritis (CIA) experimental mouse model. In several 
studies, the injection of MSCs derived from BM or AT in 
the CIA mouse model after the establishment of the 
disease improved the clinical score. Th  ese eﬀ  ects were 
associated with a decrease in Th  1-driven inﬂ  ammation 
and TNF-α or IFN-γ serum levels as well as induction of 
a regulatory T cell phenotype [51,52]. More recently, our 
group has shown that IL-6-dependent prostaglandin E2 
secretion by MSCs inhibits local inﬂ  ammation  in 
experimental arthritis [53]. However, this beneﬁ  cial eﬀ  ect 
of MSCs in rheumatoid arthritis is still controversial 
since diﬀ  erent studies have shown that the injection of 
the C3H10T1/2 MSC line, Flk-1(+) MSCs, or MSCs 
derived from DBA/1 mice did not exert a positive eﬀ  ect 
on CIA or even aggravate the symptoms [54,55]. Th  is 
discrepancy in the eﬀ  ect of MSCs may be caused by the 
diﬀ  erent sources of MSCs, but we have reported that 
altering the course of the disease depends on precise 
timing of MSC administration [53]. Th  is therapeutic 
window is likely to be associated with the immune status 
of the mice since it has been recently reported that MSCs 
are polarized towards an inﬂ   ammatory MSC1 or 
immuno  suppressive MSC2 phenotype depending on the 
type of TLR activation [30].
MSCs for treatment of chronic degenerative disorders
Osteoarthritis is the most frequent rheumatic disease 
and is characterized by degeneration of articular carti-
lage, mainly due to changes in the activity of chondro-
cytes in favor of catabolic activity. However, recent data 
now suggest that osteoarthritis also involves other joint 
tissues, with alterations of the meniscus, sclerosis and 
edema in the underlying subchondral bone as well as 
intermittent inﬂ   ammation of synovium. MSC-based 
therapy may act via two ways, either preventing cartilage 
degradation through the secretion of bioactive factors, or 
by diﬀ  erentiating into chondrocytes and contributing to 
cartilage repair. Th  e  diﬀ  erent options to deliver MSCs to 
the osteoarthritis joint have been summarized recently 
[56]. Indeed, the co-culture of human MSCs with 
primary osteoarthritis chondrocytes allowed the diﬀ  eren-
tiation of MSCs towards chondrocytes even in the 
absence of growth factors. Th  is  eﬀ  ect was dependant on 
cell-cell communication for secretion of morphogen by 
chondrocytes, suggesting that MSCs injected in a joint 
might diﬀ  erentiate into chondrocytes [57]. Secretion of 
bioactive mediators by MSCs may prevent loss of 
chondrocyte anabolic activity or stimulate progenitors 
present in the cartilage. As an example, the delivery of 
autologous MSCs to caprine joints subjected to total 
meniscectomy and resection of the anterior cruciate 
ligament resulted in regeneration of meniscal tissue and 
signiﬁ  cant chondroprotection [58]. In an experimental 
rabbit model of osteoarthritis, transplantation of a 
hyaluronan-based scaﬀ   old seeded with BM-MSCs 
statistically improved the quality of the regenerated 
tissue compared to the animal control [59]. Loss of 
proteoglycans and osteophyte formation were less in the 
animals treated with MSCs. In humans, eight clinical 
trials are currently recruiting patients to test the eﬃ   cacy 
of MSC injection for treatment of osteoarthritis. Indeed, 
a phase I/II trial is currently evaluating the eﬀ  ect of MSC 
injection with hyaluronan (in the form of ChondrogenTM) 
to prevent subsequent OA in patients undergoing 
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remain unknown, but it has been speculated that secreted 
biofactors might reduce ﬁ   brocartilage formation or 
decrease degradation by inhibiting proteinases. More-
over, although osteoarthritis is not considered an inﬂ  am-
matory disease, secretion of cytokines, namely IL-1β and 
TNF-α, and immune responses may also be suppressed 
thanks to the immunomodulatory eﬀ  ects of MSCs. Th  e 
various reports therefore argue for a therapeutic eﬃ   cacy 
of MSCs in preventing or limiting osteoarthritis lesions 
in patients.
Conclusion
Stem cell therapies represent an innovative approach for 
the treatment of diseases for which currently available 
treatments are limited. Because MSCs could operate 
through many diﬀ   erent mechanisms, MSC-based 
therapies are undergoing rapid development and have 
generated great expectations. Th   eir therapeutic potential 
is currently being explored in a number of phase I/II 
trials, and three phase III trials have been concluded for 
the treatment of graft-versus-host-disease, Crohn’s 
disease (Prochymal®, Osiris Th  erapeutics) and perianal 
ﬁ  stula (Ontaril®, Cellerix). While the data from numerous 
clinical trials are encouraging, future studies are 
obviously needed to conﬁ  rm the phase I/II studies. Th  ey 
have nevertheless paved the way for the establishment of 
feasibility and administration protocols as well as the 
safety of the procedures. Th   is should encourage initiating 
further clinical studies in non life-threatening pathologies 
such as rheumatic diseases.
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